Tyers Asset Management LLC grew its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 32.6% in the 1st quarter, Holdings Channel reports. The firm owned 7,964 shares of the biopharmaceutical company’s stock after buying an additional 1,958 shares during the period. Tyers Asset Management LLC’s holdings in Alexion Pharmaceuticals were worth $1,077,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its stake in shares of Alexion Pharmaceuticals by 25.1% in the 4th quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock worth $2,570,135,000 after acquiring an additional 5,301,272 shares during the period. Vanguard Group Inc lifted its stake in shares of Alexion Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after acquiring an additional 192,857 shares during the period. Jennison Associates LLC lifted its stake in shares of Alexion Pharmaceuticals by 17.3% in the 1st quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after acquiring an additional 1,512,545 shares during the period. Artisan Partners Limited Partnership lifted its stake in shares of Alexion Pharmaceuticals by 220.9% in the 1st quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after acquiring an additional 2,924,550 shares during the period. Finally, Norges Bank acquired a new stake in shares of Alexion Pharmaceuticals in the 4th quarter worth approximately $388,934,000. Hedge funds and other institutional investors own 94.51% of the company’s stock.
In other news, Director Bros. Advisors Lp Baker sold 123,489 shares of the stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $126.53, for a total transaction of $15,625,063.17. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.08% of the stock is currently owned by corporate insiders.
Several analysts recently commented on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $186.00 target price (up from $165.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 27th. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 17th. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, June 1st. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research report on Thursday, April 25th. Finally, Citigroup reduced their price target on shares of Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Thursday, May 23rd. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $161.06.
Alexion Pharmaceuticals stock traded up $0.38 during trading hours on Friday, hitting $117.62. The company had a trading volume of 21,692 shares, compared to its average volume of 1,419,108. The firm has a market cap of $26.36 billion, a PE ratio of 16.58, a P/E/G ratio of 0.90 and a beta of 1.58. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.36 and a current ratio of 3.87. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $92.56 and a fifty-two week high of $141.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.99 by $0.40. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The company’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.68 EPS. Equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post 8.61 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Holdings Lifted by Tyers Asset Management LLC” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2019/06/14/alexion-pharmaceuticals-inc-nasdaqalxn-holdings-lifted-by-tyers-asset-management-llc.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Article: Outstanding Shares, Buying and Selling Stocks
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.